← Eichor
Study identifier: NCT05866432 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

Condition: Breast Cancer Stage IV  ·  Sponsor: Medical University of Vienna

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.

This description comes directly from the study's public registry record.

Talk to the study team

Rupert Rupert, MD  ·  +43140400  ·  rupert.bartsch@meduniwien.ac.at

Marika Rosner  ·  +43140400  ·  marika.rosner@meduniwien.ac.at

Always discuss trial participation with your own doctor first.

Locations (1)

AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncologyVienna, State of Vienna, AustriaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05866432